$VNDA
Vanda Pharmaceuticals Inc. Stock $vnda

$vnda Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024021952 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$50.47M	$47.46M
YoY Change	9.59%	-24.06%
Cost Of Revenue	$2.733M	$3.440M
YoY Change	-21.89%	-27.94%
Gross Profit	$47.74M	$44.02M
YoY Change	12.18%	-23.74%
Gross Profit Margin	94.59%	92.75%
Selling, General & Admin	$39.47M	$30.09M
YoY Change	39.0%	-16.67%
% of Gross Profit	82.68%	68.34%
Research & Development	$16.66M	$21.15M
YoY Change	0.08%	9.97%
% of Gross Profit	34.9%	48.05%
Depreciation & Amortization	$1.968M	$206.0K
YoY Change	226.91%	-29.21%
% of Gross Profit	4.12%	0.47%
Operating Expenses	$56.14M	$51.24M
YoY Change	23.58%	-7.41%
Operating Profit	-$10.15M	-$9.235M
YoY Change	253.89%	-560.83%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$4.630M	$4.571M
YoY Change	-15.19%	29.71%
Pretax Income	-$5.516M	-$4.664M
YoY Change	-312.81%	-184.37%
Income Tax	-$1.000M	-$500.0K
% Of Pretax Income
Net Earnings	-$4.518M	-$4.146M
YoY Change	-397.24%	-227.49%
Net Earnings / Revenue	-8.95%	-8.74%
Basic Earnings Per Share	-$0.08	-$0.07
Diluted Earnings Per Share	-$0.08	-$0.07
COMMON SHARES
Basic Shares Outstanding	58.20M shares	57.54M shares
Diluted Shares Outstanding	58.22M shares	57.76M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$387.7M	$394.1M
YoY Change	-20.78%	-21.41%
Cash & Equivalents	$103.0M	$125.2M
Short-Term Investments	$284.7M	$269.0M
Other Short-Term Assets	$8.171M	$7.065M
YoY Change	-13.55%	7.16%
Inventory	$1.469M	$1.505M
Prepaid Expenses
Receivables	$41.86M	$36.71M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$439.2M	$439.4M
YoY Change	-17.68%	-17.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.303M	$2.306M
YoY Change	-76.84%	-1.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$85.91M	$84.86M
YoY Change	6.83%	3.22%
Total Long-Term Assets	$212.2M	$213.3M
YoY Change	96.15%	92.43%
TOTAL ASSETS
Total Short-Term Assets	$439.2M	$439.4M
Total Long-Term Assets	$212.2M	$213.3M
Total Assets	$651.4M	$652.7M
YoY Change	1.51%	1.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.510M	$2.237M
YoY Change	-44.81%	-34.61%
Accrued Expenses	$92.28M	$91.11M
YoY Change	9.0%	0.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$93.79M	$93.34M
YoY Change	7.32%	-0.48%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$9.059M	$8.831M
YoY Change	-37.03%	33.56%
Total Long-Term Liabilities	$9.059M	$8.831M
YoY Change	-37.03%	33.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$93.79M	$93.34M
Total Long-Term Liabilities	$9.059M	$8.831M
Total Liabilities	$108.9M	$108.7M
YoY Change	6.95%	-0.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$164.1M	-$159.5M
YoY Change	7.14%	3.16%
Common Stock	$706.9M	$703.9M
YoY Change	1.87%	1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$542.5M	$544.0M
YoY Change
Total Liabilities & Shareholders Equity	$651.4M	$652.7M
YoY Change	1.51%	1.26%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$4.518M	-$4.146M
YoY Change	-397.24%	-227.49%
Depreciation, Depletion And Amortization	$1.968M	$206.0K
YoY Change	226.91%	-29.21%
Cash From Operating Activities	-$6.928M	$7.569M
YoY Change	-47.59%	-76.2%
INVESTING ACTIVITIES
Capital Expenditures	$108.0K	$7.000K
YoY Change	96.36%	-86.27%
Acquisitions
YoY Change
Other Investing Activities	-$15.15M	-$18.21M
YoY Change	-92.06%	-109.72%
Cash From Investing Activities	-$15.26M	-$18.22M
YoY Change	-92.0%	-109.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities	-6.928M	$7.569M
Cash From Investing Activities	-15.26M	-$18.22M
Cash From Financing Activities
Net Change In Cash	-22.19M	-$10.66M
YoY Change	-89.13%	-104.87%
FREE CASH FLOW
Cash From Operating Activities	-$6.928M	$7.569M
Capital Expenditures	$108.0K	$7.000K
Free Cash Flow	-$7.036M	$7.562M
YoY Change	-47.0%	-76.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Revenues Revenues	62498000	usd
CY2023Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	4774000	usd
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58196523	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58196523	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57534499	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57534499	shares
CY2024Q1	us-gaap	Revenues Revenues	47462000	usd
CY2024Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	3440000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21154000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19237000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30085000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36104000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2018000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	379000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	56697000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	60494000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9235000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2004000	usd
CY2024Q1	us-gaap	Other Income OtherIncome	4571000	usd
CY2023Q1	us-gaap	Other Income OtherIncome	3524000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4664000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5528000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-518000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2276000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4146000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	3252000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57760940	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57011396	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57760940	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57400152	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4146000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	3252000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-19000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	9000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-430000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	1206000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-96000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	277000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-353000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	938000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4499000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4190000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	544910000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3584000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4146000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-353000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	543995000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	527198000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4351000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	3252000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	938000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	535739000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4146000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	3252000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	206000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	291000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3584000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4351000	usd
CY2024Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1466000	usd
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2288000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-655000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2018000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	379000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-246000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2014000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-641000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1109000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2587000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8901000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1781000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11345000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-29000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-74000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1165000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10791000	usd
CY2024Q1	vnda	Increase Decrease Product Revenue Allowances IncreaseDecreaseProductRevenueAllowances	6590000	usd
CY2023Q1	vnda	Increase Decrease Product Revenue Allowances IncreaseDecreaseProductRevenueAllowances	12511000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7569000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	31803000	usd
CY2024Q1	vnda	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	2705000	usd
CY2023Q1	vnda	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	76006000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	163045000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	60500000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	350390000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18218000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	187294000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-14000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10663000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	219142000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136290000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135498000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125627000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	354640000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	vnda	Number Of Products In Portfolio NumberOfProductsInPortfolio	3	product
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125158000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	354171000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	469000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	469000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125627000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	354640000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47462000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62498000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	269491000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	19000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	526000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	268984000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	252520000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	229000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	306000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	252443000	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	307355000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	316211000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	27000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1505000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1330000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1505000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1357000	usd
CY2024Q1	vnda	Inventory Raw Materials Net Of Reserves Non Current InventoryRawMaterialsNetOfReservesNonCurrent	934000	usd
CY2023Q4	vnda	Inventory Raw Materials Net Of Reserves Non Current InventoryRawMaterialsNetOfReservesNonCurrent	934000	usd
CY2024Q1	vnda	Inventory Work In Process Net Of Reserves Non Current InventoryWorkInProcessNetOfReservesNonCurrent	7066000	usd
CY2023Q4	vnda	Inventory Work In Process Net Of Reserves Non Current InventoryWorkInProcessNetOfReservesNonCurrent	7177000	usd
CY2024Q1	vnda	Inventory Finished Goods Net Of Reserves Non Current InventoryFinishedGoodsNetOfReservesNonCurrent	411000	usd
CY2023Q4	vnda	Inventory Finished Goods Net Of Reserves Non Current InventoryFinishedGoodsNetOfReservesNonCurrent	737000	usd
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	8411000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	8848000	usd
CY2024Q1	vnda	Inventory Inventory	9916000	usd
CY2023Q4	vnda	Inventory Inventory	10205000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	137894000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18543000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	119351000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	137894000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16525000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	121369000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	119351000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	5255000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7007000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7007000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7007000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	7007000	usd
CY2024Q1	vnda	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	86068000	usd
CY2024Q1	vnda	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	15008000	usd
CY2023Q4	vnda	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	15691000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	11398000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4404000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2410000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2398000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2378000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6413000	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2237000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2409000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4342000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7145000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	37773000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	38460000	usd
CY2024Q1	vnda	Agreements For Clinical And Marketing Services Termination Notice Period AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod	P90D
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	2000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	21000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-385000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-51000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-383000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-30000	usd
CY2024Q1	vnda	Share Based Compensation Option Awards Contractual Term ShareBasedCompensationOptionAwardsContractualTerm	P10Y
CY2024Q1	vnda	Share Based Compensation Arrangementby Share Based Payment Annual Award Vesting Period Employeesand New Directors ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors	P4Y
CY2024Q1	vnda	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards	0.25
CY2024Q1	vnda	Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards	0.75
CY2024Q1	vnda	Sharebased Compensation Arrangementby Share Based Payment Award Options Vesting Period Number Of Equal Monthly Installments SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments	36	installment
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.57
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57760940	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57400152	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3584000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4351000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.47
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0392
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-500000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2300000	usd
CY2024Q1	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	500000	usd
CY2023Q1	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1100000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4146000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	3252000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57760940	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57011396	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	388756	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7029644	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6133050	shares
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-021952-index-headers.html	Edgar Link	pending
0001628280-24-021952-index.html	Edgar Link	pending
0001628280-24-021952.txt	Edgar Link	pending
0001628280-24-021952-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vnda-20240331.htm	Edgar Link	pending
vnda-20240331.xsd	Edgar Link	pending
vndaex311331202410q.htm	Edgar Link	pending
vndaex312331202410q.htm	Edgar Link	pending
vndaex321331202410q.htm	Edgar Link	pending
vnda-20240331_def.xml	Edgar Link	unprocessable
vnda-20240331_lab.xml	Edgar Link	unprocessable
vnda-20240331_pre.xml	Edgar Link	unprocessable
vnda-20240331_htm.xml	Edgar Link	completed
vnda-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VNDA
Vanda Pharmaceuticals Inc. Stock $vnda

2024 Q2 Form 10-Q Financial Statement

#000162828024021952 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VNDA Vanda Pharmaceuticals Inc. Stock $vnda

2024 Q2 Form 10-Q Financial Statement

#000162828024021952 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VNDA
Vanda Pharmaceuticals Inc. Stock $vnda